drugset / Trial / NCT01209325
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Phase 2
Completed
149 enrolled
AIDS Malignancy Consortium
AIDS and Cancer Specimen Resource · collabMerck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collabThe Emmes Company, LLC · collabUniversity of Arkansas · collab
NaSingle-groupOpen-labelPrevention
Summary
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.
Timeline
- Start
- 2011-06-28
- Primary completion
- 2017-12-12
- Completion
- 2017-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gardasil | Vaccine | — | — |